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Abstract: Brinzolamide 1%/timolol 0.5% is a new fixed-combination for the treatment of 
open-angle glaucoma or ocular hypertension. Brinzolamide/timolol has a favorable safety 
profile, with an incidence of ocular burning and stinging 5%. Published data show that 
brinzolamide 1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% have similar efficacies for 
lowering intraocular pressure (IOP). There is some evidence that brinzolamide/timolol may 
be more comfortable. Although patients receiving brinzolamide/timolol may experience more 
blurred vision on instillation, some data show a preference for brinzolamide/timolol over 
dorzolamide/timolol. Although available data to assess the role of brinzolamide/timolol in daily 
clinical practice are still limited, these first results suggest the agent to be a reasonable alternative 
for patients who do not reach target IOP with monotherapy.
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Introduction
Reduction of elevated intraocular pressure (IOP) is the only proven approach to 
protect against visual field loss in patients with open-angle glaucoma (OAG) or ocular 
hypertension (OHT), making ocular hypotensive agents critical to the management of 
these patients. First-line therapy for elevated IOP is typically a single topical agent from 
one of the following classes of drugs: alpha-2 adrenergic receptor agonists, beta-blockers, 
topical carbonic anhydrase inhibitors (CAIs), and prostaglandin derivatives/prostamides.1 
If single-agent therapy is effective but not sufficient to reach a patient’s target IOP, a second 
hypotensive drug is added. Evidence shows that this strategy can produce an additional 
IOP decrease.2 The 2-drug combination can be comprised of 2 individual agents or 
a fixed-combination product. A recent meta-analysis confirmed that these 2 types of 
glaucoma therapies produce equivalent efficacy.3 In a large study (N = 3333) of patients 
taking glaucoma medications, the majority (79%) reported that they were satisfied with 
their eye drops; however, nearly 1 in 10 patients (9%) were likely to have their medication 
changed at their next visit due to side effects.4 Each hypotensive agent has a characteristic 
side effect profile, but fixed-combination products as a group have a number of advantages 
over the instillation of 2 individual drugs.5 First, a fixed-combination product requires 
dispensing from only 1 bottle, making it more convenient than dispensing 2 separate 
doses. The European Glaucoma Society recommended that fixed-combination products be 
used, whenever available, in place of 2 separate instillations.1 Fixed-combination products Clinical Ophthalmology 2009:3 594
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also avoid washout, which occurs when inadequate time is 
allowed between instillation of the first and second drugs.6 
Moreover, the lifetime exposure to preservatives is reduced 
with fixed-combination products. Because preservatives 
have been shown to be associated with both in vitro ocular 
toxicities (eg, cellular apoptosis, conjunctival inflammation),7,8 
and clinical signs and symptoms of ocular irritation (eg, dry 
eye, burning/stinging, discomfort),9,10 reducing exposure 
to preservatives should facilitate the maintenance of ocular 
surface health in these patients requiring chronic topical 
therapies. Finally, costs and impact on quality of life can 
lead to non-compliance in patients who have to use multiple 
medications. Some of these disadvantages can also be reduced 
by using fixed combinations.11
The fixed-combination dorzolamide 2%/timolol 0.5% 
(Cosopt®; Merck & Co., Inc., Whitehouse Station, NJ, 
USA) has been shown to be at least as effective as separate 
instillations of the component drugs.12 Side effects that 
have been described are ocular stinging and burning 
upon instillation and a bitter taste.13 The safety profiles 
of the individual components show that the incidence of 
stinging and burning of the fixed-combination product is 
most similar to dorzolamide (Trusopt®; Merck & Co., Inc., 
Whitehouse Station, NJ, USA) alone.14 Recently, the fixed 
combination dorzolamide/timolol has also become available 
in several countries in a preservative-free variant. Recently, 
a new fixed-combination product, brinzolamide 1%/timolol 
0.5% (Azarga®; Alcon Laboratories, Inc., Fort Worth, TX, 
USA), has been introduced. The aim of this review article 
is to explore the molecular and clinical characteristics of 
brinzolamide/timolol to determine its potential role in the 
management of patients with OAG or OHT.
Brinzolamide 1%/timolol 0.5%
The brinzolamide/timolol fixed combination is comprised 
of the CAI brinzolamide and the beta-blocker timolol 
and is recommended to be dosed twice daily (bid).15 It is 
delivered as a suspension with a pH of 7.2 and is preserved 
with benzalkonium chloride 0.01%.15 The concentration of 
brinzolamide is 1% (10 mg/mL), equal to that of brinzolamide 
ophthalmic suspension (Azopt®; Alcon Laboratories, Inc., 
Fort Worth, TX, USA)16 and the timolol concentration is 0.5% 
(5 mg/mL), equal to that of single-agent timolol.17–19
Mechanisms of action  
and pharmacokinetics
Brinzolamide is a highly specific, reversible inhibitor of 
carbonic anhydrase, an enzyme which is present in the lens, 
cornea, ciliary body and retina.20,21 Blocking this enzyme is 
believed to reduce aqueous humor formation by slowing the 
formation of bicarbonate ions with subsequent reduction 
in sodium and fluid transport.16 Brinzolamide-induced 
inhibition of CA II, a key carbonic anhydrase isoenzyme, 
occurs both during the day and at night, apparently not 
subjected to the circadian rhythm.22,23 A single drop of 
brinzolamide can lower IOP for approximately 12 hours, 
and its washout time after chronic instillation is 7 days.22
Contraindications of topical carbonic anhydrase 
inhibitors are renal failure and sulfonamide allergy. Caution 
should be taken in patients with a compromised corneal 
endothelium.
Beta-adrenergic antagonists (beta blockers) reduce IOP 
through blocking of the B1-adrenoreceptor (non-selective 
and selective beta blockers) and B2-adrenoreceptors 
(non-selective beta blockers) of the ciliary body epithelium 
which leads to a reduced inflow of aqueous humor in the 
anterior chamber of the eye. Most beta blockers are dosed 
bid, although the gel-forming solutions are often equally 
efficacious in a once daily regime.24–26 The activity of timolol 
is subject to circadian changes, showing less efficacy at 
night.27 Contraindications for the use of timolol are asthma, 
obstructive pulmonary disease, sinus bradycardia and 
heart block.
Effect on ocular blood flow
Some aspects of ocular blood flow may be reduced in certain 
patients with glaucoma.28 Reduced ocular perfusion pressure 
probably is an independent risk factor for the development 
of OAG.29–34
Numerous studies have shown that timolol does not 
affect ocular blood flow;35–37 however, several studies have 
reported a possible increased resistance to blood flow.38,39 
Although there is no conclusive evidence, many studies 
have suggested that the topical carbonic anhydrase inhibitor 
dorzolamide probably has a positive effect on ocular blood 
flow. In addition, a positive effect on ocular blood flow for 
the fixed combination of dorzolamide/timolol has been 
shown.40–46 The effect of brinzolamide on ocular blood flow 
is less well established, mainly due to a limited number of 
publications on the subject. Several studies have shown that 
brinzolamide positively affects ocular blood flow,47–49 but 
others have shown no effect.50,51 Until now, the effects of 
brinzolamide/timolol on ocular blood flow have been unclear. 
Studies on the effects of the combination brinzolamide/
timolol (concomitant or fixed combination) on ocular blood 
flow are scarce.Clinical Ophthalmology 2009:3 595
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IOP-lowering efficacy
We performed a systematic review of the IOP-lowering 
efficacy of the combination of brinzolamide and timolol. 
Articles were identified through a computerized search 
in Medline, Embase, and the Cochrane Controlled Trials 
Register. For details on search strategy, selection process 
and data extraction we refer to the papers of van der Valk 
et al52 and Webers et al2,53 Potentially eligible for inclusion in 
this systematic review were randomized clinical trials on the 
combination of timolol and brinzolamide written in English, 
French, German or Dutch and published between January 
1995 and July 2009.
The initial search revealed 1169 papers. Based on the 
title, abstract and medical subject heading (MeSH) words, 
1128 papers were excluded. The most important reasons 
for excluding articles were that the primary endpoint in the 
studies was not IOP but, for instance, side-effects, visual field 
outcome or impact on ocular blood flow, that articles reported 
on glaucoma topics other than IOP lowering of drugs, or that 
studies reported on IOP lowering of monotherapies. From 
the remaining 41 papers that were printed or photocopied 
36 papers had to be excluded. The major reasons were a 
non-randomize design (n = 9), a combination of other drugs 
(n = 7) or a different outcome parameter (n = 9).
The results of the included studies54–58 are shown in 
Table 1.
An earlier systematic review showed no significant 
differences between concomitant and fixed use of the 
combination of 0.5% timolol bid and 2% dorzolamide bid.2 
The mean additional IOP decrease of 2% dorzolamide bid 
or tid when added to 0.5% timolol bid was 15.7% at trough 
and 20.1% at peak.53 The present study gives similar results 
for the IOP decrease of the concomitant use of 0.5% timolol 
bid and 1% brinzolamide bid or tid, varying between 13.2% 
at trough and 20.3% at peak. The 2 papers reporting on 
the fixed combination brinzolamide/timolol57,58 revealed 
similar IOP-lowering results. These studies both used a 
washout design. Moreover, the Manni study58 also reported 
similar IOP-lowering results for the brinzolamide/timolol 
combination when directly compared with the fixed 
combination dorzolamide/timolol.
Safety and tolerability
In the study by Kaback57 et al a higher incidence of blurred 
vision was found in the group of patients treated with 
brinzolamide/timolol versus patients treated with timolol 
0.5% alone; however, reported dysgeusia was markedly lower 
with the fixed combination. The Manni study showed similar 
safety profiles for brinzolamide/timolol and dorzolamide/
timolol, with the exceptions of a lower incidence of any 
adverse events and fewer patients with ocular burning 
and stinging. In the brinzolamide/timolol group, a higher 
incidence of blurred vision was reported.58
A study by Vold and colleagues59 directly examined the 
ocular discomfort associated with the use of brinzolamide/
timolol or dorzolamide/timolol after 1 week of dosing. 
Mean ocular discomfort scores (judged from a scale of 
0 [none] to 4 [very severe]) were significantly lower in 
patients receiving brinzolamide/timolol than in those receiv-
ing dorzolamide/timolol. Although this study had a very 
short follow-up period, the results confirm the results from 
the Manni study.
Because  the  beta-blocker  component  of  the  2 
CAI-containing fixed-combination products is identical, 
any dissimilarities in tolerability are likely due to differences 
in pH between brinzolamide and dorzolamide. Dorzolamide/
timolol is formulated at an acidic pH of 5.65,13 whereas 
brinzolamide/timolol has a near physiologic pH of 7.2.15 This 
hypothesis is supported by results from 2 multicenter studies 
published in 2000 which used study designs similar to the Vold 
comfort study, comparing the ocular comfort of the single 
agents brinzolamide and dorzolamide.60 Significantly more 
patients in both studies reported no ocular discomfort with 
brinzolamide than with dorzolamide. In an ocular discomfort 
study in which patients taking latanoprost, dorzolamide, and 
timolol combination therapy were randomized to switch the 
CAI component to brinzolamide or to continue dorzolamide, 
patients in the brinzolamide group, but not the control 
group, experienced a significant decrease in ocular irritation, 
although these patients had a numerical increase in blurred 
vision.61 Another study from Michaud and colleagues, which 
compared brinzolamide and dorzolamide each given twice 
daily in addition to timolol 0.5%, also found significantly less 
ocular burning and stinging in the brinzolamide group.55
The results from the studies mentioned above suggest that 
brinzolamide/timolol may be more tolerable than (preserved) 
dorzolamide/timolol, at the cost of an increase in blurred 
vision. The authors are not aware of any studies comparing 
the ocular comfort of unpreserved dorzolamide/timolol to 
preserved dorzolamide/timolol or other topical medication.
Patient preference
All of the clinical characteristics described above – efficacy, 
safety, and tolerability – probably affect patient preference. 
Patient preference, in turn, may improve adherence. 
Barnebey et al suggested that better patient adherence after Clinical Ophthalmology 2009:3 596
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Table l Run-in medication, treatment combination after adding brinzolamide, baseline characteristics, time point(s) of intraocular pressure 
measurements and absolute (mmHg) and relative (%) decrease from baseline intraocular pressure for peak and trough time points
  
Trial Run-in  
medication
Treatment combination 
after run-in
No. of patients 
baseline (% with-
drawals)
Sex (M/F) Mean age (y) POAG (%) OHT (%) Endpoint of  
measurement  
(months)
Baseline IOP  
(mmHg)  
mean ± SD
Time point(s) of 
IOP measurements
IOP decrease 
(mmHg)  
mean ± SD
IOP decrease 
(%) mean ± SD
Trough
Shin 200054 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide tid
53 (11.3) 28/25 61 59 41 1 25.5 ± nr +0 timolol 
+0 brinzolamide
–3.3 ± nr –13.2 ± nr
Michaud et al 200155 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
104 (6.7) 54/50 nr 57 37 1 25.5 ± 1.9 +0 timolol  
+0 brinzolamide
–3.6 ± 3.0 –14.1 ± 11.4
Martinez et al 200956 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
76 (54) 41/35 64 100 0 60 22.7 ± 1.2 nr –4.3 ± nr –18.9 ± nr
Kaback et al 200857 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
171 (7.5) 80/91 nr 63 37 3 27.1 ± 2.7 +0 timolol  
+0 brinzolamide
–8.3 ± 3.8 –30.6 ± 13.6
Manni et al 200958 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
220 (7.3) 96/124 65 78 22 3 27.3 ± nr +0 timolol  
+0 brinzolamide
–9.1 ± nr –33.3 ± nr
Peak
Shin 200054 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide tid
53 (11.3) 28/25 61 59 41 1 25.5 ± nr +2 timolol  
+2 brinzolamide
–3.3 ± nr –14.3 ± nr
Michaud et al 200155 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
104 (6.7) 54/50 nr 57 37 1 25.5 ± 1.9 +2 timolol  
+2 brinzolamide
–4.9 ± 2.6 –20.3 ± 10.5
Martinez et al 200956 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
76 (54) 41/35 64 100 0 60 22.7 ± 1.2 nr –4.3 ± nr –18.9 ± nr
Kaback et al 200857 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
171 (7.5) 80/91 nr 63 37 3 25.8 ± 3.0 +2 timolol  
+2 brinzolamide
–8.7 ± 3.9 –33.7 ± 14.7
Manni et al 200958 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
220 (7.3) 96/124 65 78 22 3 25.9 ± nr +2 timolol  
+2 brinzolamide
–9.1 ± nr –34.9 ± nr
Abbreviations: M, male; F, female;   Y, year; POAG, primary open-angle glaucoma; OHT, ocular hypertension; IOP, intraocular pressure; SD, standard deviation; bid, twice daily; 
tid, thrice daily; nr, not reported.
a transition from dorzolamide to brinzolamide correlated 
with a patient preference for brinzolamide.62 In a crossover 
study, Mundorf and colleagues found better comfort scores 
for brinzolamide/timolol than for dorzolamide/timolol.63 
Although the follow up in this study was very limited, 
a majoritiy of patients preferred brinzolamide/timolol. 
Ocular burning and stinging are very frequent side effects 
of topical glaucoma medications.4 In a willingness-to-pay 
analysis of topical ocular medications, it was found that 
nearly 75% of patients would be willing to pay a premium 
for a medication that would eliminate stinging and burning 
upon instillation.64
Summary
Published data show that brinzolamide 1%/timolol 0.5% 
and dorzolamide 2%/timolol 0.5% have similar efficacies 
for lowering IOP. The main difference between these agents 
appears to be in the safety profiles, with dorzolamide/
timolol producing more ocular burning and stinging, 
probably due to differences in pH. In several studies, 
brinzolamide/timolol was rated as the more comfortable 
medication for new users. Although patients receiving 
brinzolamide/timolol may experience more blurred vision 
upon instillation, some data suggest a preference for 
brinzolamide/timolol over dorzolamide/timolol in new users. 
However, the follow up of these studies was short or very 
short. Patients who have used their medication for a longer 
period may probably be more satisfied with their medication. 
The effect of excluding preservatives in dorzolamide/timolol 
on comfort and/or patient preference has not been studied.
Thus, although available data to assess the role of 
brinzolamide/timolol are still limited, its apparently similar 
efficacy and probably improved tolerability relative to 
dorzolamide/timolol make it a reasonable alternative for 
patients who do not reach target IOP with monotherapy. 
Further evaluation of the fixed combination brinzolamide/
timolol in daily clinical practice will elucidate how this 
novel combination agent will be accepted by physicians and 
ultimately incorporated into the management of patients 
with elevated IOP.Clinical Ophthalmology 2009:3 597
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Table l Run-in medication, treatment combination after adding brinzolamide, baseline characteristics, time point(s) of intraocular pressure 
measurements and absolute (mmHg) and relative (%) decrease from baseline intraocular pressure for peak and trough time points
  
Trial Run-in  
medication
Treatment combination 
after run-in
No. of patients 
baseline (% with-
drawals)
Sex (M/F) Mean age (y) POAG (%) OHT (%) Endpoint of  
measurement  
(months)
Baseline IOP  
(mmHg)  
mean ± SD
Time point(s) of 
IOP measurements
IOP decrease 
(mmHg)  
mean ± SD
IOP decrease 
(%) mean ± SD
Trough
Shin 200054 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide tid
53 (11.3) 28/25 61 59 41 1 25.5 ± nr +0 timolol 
+0 brinzolamide
–3.3 ± nr –13.2 ± nr
Michaud et al 200155 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
104 (6.7) 54/50 nr 57 37 1 25.5 ± 1.9 +0 timolol  
+0 brinzolamide
–3.6 ± 3.0 –14.1 ± 11.4
Martinez et al 200956 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
76 (54) 41/35 64 100 0 60 22.7 ± 1.2 nr –4.3 ± nr –18.9 ± nr
Kaback et al 200857 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
171 (7.5) 80/91 nr 63 37 3 27.1 ± 2.7 +0 timolol  
+0 brinzolamide
–8.3 ± 3.8 –30.6 ± 13.6
Manni et al 200958 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
220 (7.3) 96/124 65 78 22 3 27.3 ± nr +0 timolol  
+0 brinzolamide
–9.1 ± nr –33.3 ± nr
Peak
Shin 200054 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide tid
53 (11.3) 28/25 61 59 41 1 25.5 ± nr +2 timolol  
+2 brinzolamide
–3.3 ± nr –14.3 ± nr
Michaud et al 200155 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
104 (6.7) 54/50 nr 57 37 1 25.5 ± 1.9 +2 timolol  
+2 brinzolamide
–4.9 ± 2.6 –20.3 ± 10.5
Martinez et al 200956 0.5% timolol bid 0.5% timolol bid and 1% 
brinzolamide bid
76 (54) 41/35 64 100 0 60 22.7 ± 1.2 nr –4.3 ± nr –18.9 ± nr
Kaback et al 200857 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
171 (7.5) 80/91 nr 63 37 3 25.8 ± 3.0 +2 timolol  
+2 brinzolamide
–8.7 ± 3.9 –33.7 ± 14.7
Manni et al 200958 washout 0.5% timolol/1% 
brinzolamide bid (fixed)
220 (7.3) 96/124 65 78 22 3 25.9 ± nr +2 timolol  
+2 brinzolamide
–9.1 ± nr –34.9 ± nr
Abbreviations: M, male; F, female;   Y, year; POAG, primary open-angle glaucoma; OHT, ocular hypertension; IOP, intraocular pressure; SD, standard deviation; bid, twice daily; 
tid, thrice daily; nr, not reported.
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